Drugmakers are pouring billions of dollars into new US manufacturing. It still won’t achieve all of Trump’s tariff goals

Major pharmaceutical companies, including AstraZeneca, Johnson & Johnson, and Eli Lilly, have announced over $250 billion in U.S. manufacturing investments, largely in response to President Trump's tariff threats aimed at boosting domestic production and lowering drug prices. However, industry experts express skepticism, asserting that many of these commitments pre-date the threats or are unlikely to significantly reduce reliance on foreign ingredients or lower consumer costs due to higher U.S. production expenses and complex pricing. Crucially, generic drugmakers, which account for 90% of U.S. prescriptions, are largely unable to make similar investments due to thin margins, and tariffs could even prompt market withdrawal rather than increased domestic production for this critical segment.

Analysis

Major pharmaceutical companies, including AstraZeneca ($50B), Johnson & Johnson ($55B), and Eli Lilly ($27B), have announced over $250 billion in US manufacturing investments, primarily in response to the Trump administration's threat of tariffs aimed at reshoring production. However, these commitments are met with considerable skepticism from industry experts, who note that some initiatives were pre-planned and that the moves are unlikely to reduce reliance on foreign-sourced pharmaceutical ingredients or lower costs for American consumers. A critical divergence exists between brand-name companies, which possess the financial flexibility to make these strategic investments to mitigate tariff impacts, and generic drug manufacturers. The generic sector, which accounts for over 90% of US prescriptions, operates on thin margins and largely cannot afford to reshore production. Consequently, tariffs pose a significant risk of forcing generic drugmakers to exit the US market, which would exacerbate drug shortages and undermine the policy's stated national security objectives. The prevailing uncertainty over the final tariff rates and scope creates a challenging environment for long-term capital allocation, as building new facilities requires a 3-5 year timeline that extends beyond predictable political cycles.

Key Decisions for Investors

• Investors should differentiate between large-cap, brand-name pharmaceutical companies like AZN and JNJ, which are proactively de-risking from tariffs through domestic investment, and the more vulnerable generic drug sector, where tariffs pose a significant threat to profitability and market presence.
• Treat corporate investment announcements with caution, as analysts suggest they may be politically motivated or represent previously planned projects; focus instead on monitoring concrete details of the administration's final tariff policies, which is the primary driver of risk and opportunity.
• Evaluate companies with specialized US manufacturing in areas like sterile injectables, such as Amphastar, which may be positioned to benefit from targeted reshoring incentives, while scrutinizing generic drugmakers for signs of market stress or withdrawal if broad tariffs are implemented.
• Acknowledge the heightened political and regulatory risk across the sector, as the 3-5 year investment cycle for new manufacturing facilities clashes with the significant uncertainty of trade policies and future administrations.